CD276 CAR-NK cells therapy (Hrain Biotechnology)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameCD276 CAR-NK cells therapy (Hrain Biotechnology)
Drug Alias NameHR-018HR018
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A